Pharmaceutical

In a preliminary injunction, a Californian superior court judge has stepped between two major institutions arguing over a major Alzheimer’s disease research and development program that has the potential to benefit the pharmaceutical industry.

In a preliminary injunction, a Californian superior court judge has stepped between two major institutions arguing over a major Alzheimer’s disease research and development program that has the potential to benefit the pharmaceutical industry.
According to Fierce Biotech:

A superior court judge has demanded USC, which poached [Paul] Aisen and some of the program’s key researchers from UC San Diego in June, to take its hands off of the initiative until a related lawsuit from UCSD is resolved. That means returning to UCSD all data and systems related to the Alzheimer’s Disease Cooperative Study (ADCS), a National Institutes of Health-partnered initiative that has run 30 trials on potential new drugs since its foundation in 1991.
UCSD has managed ADCS since its inception, appointing the high-profile researcher Aisen to oversee the program in 2007. But USC lured Aisen away last month with the promise of a $500,000 salary, bringing with him 8 top Alzheimer’s researchers in what UCSD claims was an effort to wrest control of ADCS and get in line for the high-dollar grants attached to the program. In its lawsuit, UCSD claimed Aisen and his colleagues transferred loads of data from ADCS onto an Amazon hosting account of their own, repeatedly refusing to disclose the password to school officials.

Click here to read the full article on Fierce Biotech.

MARKETS

Markets
TSX19065.26+203.90
TSXV621.75+4.49
DOW31097.26+321.83
S&P 5003825.33+39.95
NASD11127.85+99.11
ASX6539.90-28.20

COMMODITIES

Commodities
Gold1807.22-1.19
Silver19.93+0.07
Copper3.57-0.14
Palladium1941.50-3.50
Platinum887.00+1.00
Oil110.57+4.81
Heating Oil3.95+0.12
Natural Gas5.84+0.23

DOWNLOAD FREE REPORTS

×